Arcus Biosciences, Inc. cotiza a 24.34 USD y tiene una capitalización bursátil de $3.1B. En los últimos 12 meses ha facturado $117M con un margen de flujo de caja libre del -195.9%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Ph…
| Periodo | 2026-10 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.72 | $-1.02 | $-0.89 |
| Estimado | $-0.86 | $-0.81 | $-0.83 | $-1.07 |
| Sorpresa | — | +11.1% | -22.9% | +16.8% |
| Métrica | RCUS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -156.3% | -38.6% | -117.7% |
| Net Margin | -142.9% | -33.6% | -109.3% |
| FCF Margin | -195.9% | -13.9% | -182.1% |
| ROE | -55.9% | -40.4% | -15.5% |
| ROA | -31.0% | -32.0% | +1.0% |
| Current Ratio | 4.36 | 2.84 | +1.52 |
| Debt / Equity | 0.16 | 0.28 | -0.12 |